Alkermes PLC ALKS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress
Alkermes to Present at Upcoming Investor Conferences
Alkermes plc Reports Third Quarter 2026 Financial Results
Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)
Alkermes to Report Third Quarter Financial Results on November 3, 2026
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research
Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors
Trading Information
- Previous Close Price
- $46.47
- Day Range
- $46.08–47.54
- 52-Week Range
- $26.99–55.64
- Bid/Ask
- $47.26 / $47.44
- Shares Outstanding
- 168.04M
- Market Cap
- $7.97B
- Volume/Avg
- 419,692 / 2M
Key Statistics
- Price/Earnings (Normalized)
- 27.31
- Price/Sales
- 4.44
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 0.35%
Company Profile
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 2,050
- Website
- https://www.alkermes.com
Competitors
Valuation
Metric | ALKS | JNJ |
|---|---|---|
Price/Earnings (Normalized) | 27.31 | 26.36 |
Price/Book Value | 4.19 | 8.29 |
Price/Sales | 4.44 | 6.91 |
Price/Cash Flow | 25.27 | 31.90 |
Price/Earnings
ALKS
JNJ
Financial Strength
Metric | ALKS | JNJ |
|---|---|---|
Quick Ratio | 1.86 | 0.65 |
Current Ratio | 2.42 | 1.02 |
Interest Coverage | 0.76 | 18.14 |
Quick Ratio
ALKS
JNJ
Profitability
Metric | ALKS | JNJ |
|---|---|---|
Return on Assets (Normalized) | 3.59% | 13.13% |
Return on Equity (Normalized) | 7.17% | 31.88% |
Return on Invested Capital (Normalized) | 6.36% | 20.08% |
Return on Assets
ALKS
JNJ
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|s<kb$CJN | LOCK|B#WT? | $73B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|tz&K&@v | LOCK|&XcXJ | $50B | |||
| Haleon PLC ADR HLN | LOCK|!&vbLZZ | LOCK|h> | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|%yd^xMM> | LOCK|># | $34B | |||
| Viatris Inc VTRS | LOCK|Cm<nrN? | LOCK|$d@ | $24B | |||
| Elanco Animal Health Inc ELAN | LOCK|W? | LOCK|@!j | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|?Mm#v# | LOCK|#&g | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|<&zpZjs | LOCK|tF$ | $4B | |||
| Perrigo Co PLC PRGO | LOCK|>d!dVh! | LOCK|#vb | $2B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|ch$qK@ | LOCK|t>@kn | $2B |
United States